Regeneron Pharmaceuticals Inc.
Revenue
$2B
Net Income
$1B
Regeneron Pharmaceuticals Inc.
Revenue
$2B
Net Income
$1B
Regeneron Pharmaceuticals Inc.
CIK: 0000872589
Earnings Analysis
Analyzed 11 of 12 reports
Performance Summary - Q3 2025bullish (65)maintained
Reality-Based Sentiment Analysisbullish65/100
Based on actual market data, not just management spin. Weighted score: 10% management tone + 40% earnings beat/miss + 30% price action + 20% guidance accuracy.
Financial Performance Trend
Overall Analysis & Outlook
Over the past 5 quarters, Regeneron Pharmaceuticals Inc. has been consistently bullish with stable guidance. Revenue has declined 49.8% during this period. The latest quarter shows bullish sentiment with positive tone from management.
Latest Quarter Highlights:
Regeneron delivered strong quarterly results with robust revenue and net income, driven by key product sales and collaborative partnerships. The company continues to defend its intellectual property through extensive patent litigation while maintaining a positive financial outlook.
Detailed Quarterly Reports
In-depth analysis of each quarter's earnings filing
Q3 2025
10-Q • Filed 10/28/2025
Summary
Regeneron delivered strong quarterly results with robust revenue and net income, driven by key product sales and collaborative partnerships. The company continues to defend its intellectual property through extensive patent litigation while maintaining a positive financial outlook.
Revenue
$1.59B
Net Income
$1.46B
Guidance
Tone
Capex
$649.7M
Partnerships
Key Quotes
"Continued strong performance across our product portfolio"
"Successfully defending our intellectual property through strategic legal proceedings"
Q2 2025
10-Q • Filed 8/1/2025
Summary
Regeneron delivered strong Q2 2025 financial performance with robust revenue and net income. The company continues to defend its key drug EYLEA through multiple patent litigation cases and maintains strategic collaborations with Sanofi and Bayer.
Revenue
$1.63B
Net Income
$1.39B
Guidance
Tone
Capex
$448.3M
Partnerships
Key Quotes
"The company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies"
"Sanofi is generally responsible for funding 80% to 100% of agreed-upon development costs"
Q1 2025
10-Q • Filed 4/29/2025
Summary
Regeneron delivered strong Q1 2025 financial results with robust revenue growth driven by Dupixent and continued profitability. The company maintains a positive outlook despite ongoing patent litigation challenges.
Revenue
$3.03B
Net Income
$808.7M
Guidance
Tone
Capex
$229.3M
Partnerships
Key Quotes
"Our core business strategy is to maintain a strong foundation in scientific research and drug development using our proprietary technologies"
"We continue to advance as an integrated, multi-product biotechnology company"
Q4 2024
10-K • Filed 2/5/2025
Summary
Regeneron faces increasing competition and regulatory challenges, particularly for its key products EYLEA and Dupixent. The company continues to expand its workforce and relies heavily on collaborations with Sanofi and Bayer.
Revenue
$3.99B
Net Income
N/A
Guidance
Tone
Partnerships
Key Quotes
"We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent."
"Attracting, developing, and retaining skilled and experienced employees is crucial to our ability to compete effectively."
Q3 2024
10-Q • Filed 10/31/2024
Summary
Regeneron delivered strong quarterly performance with robust revenue and net income growth. The company continues to defend its key drug patents and maintain strategic collaborations while facing some regulatory scrutiny.
Revenue
$1.95B
Net Income
$1.34B
Guidance
Tone
Capex
$556.3M
Partnerships
Key Quotes
"Continued strength in EYLEA and collaboration revenues"
"Successful patent defense strategies across multiple geographies"
Q2 2024
10-Q • Filed 8/1/2024
Summary
Regeneron delivered strong quarterly performance with revenue of $1.92B and net income of $1.43B, driven by continued growth in key products like EYLEA. The company maintains a robust pipeline and strategic collaborations while navigating ongoing patent litigation.
Revenue
$1.92B
Net Income
$1.43B
Guidance
Tone
Capex
$314.4M
Partnerships
Key Quotes
"Our core business strategy is to maintain a strong foundation in basic scientific research and discovery-enabling technologies"
"We continue to advance as an integrated, multi-product biotechnology company"
Q1 2024
10-Q • Filed 5/2/2024
Summary
Regeneron delivered stable financial performance in Q1 2024, with consistent revenues and solid net income. The company continues to leverage its diverse product portfolio and strategic collaborations while managing ongoing legal and regulatory challenges.
Revenue
$3.15B
Net Income
$722M
Guidance
Tone
Capex
$133.9M
Partnerships
Key Quotes
"Our core business strategy is to maintain a strong foundation in basic scientific research and discovery-enabling technologies"
"Regeneron is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases"
Q4 2023
10-K • Filed 2/5/2024
Summary
Regeneron faces significant headwinds from potential Medicare drug pricing reforms, biosimilar competition for EYLEA, and increasing regulatory complexity. The company remains substantially dependent on EYLEA and Dupixent, with concentrated customer base and weak pricing power.
Revenue
N/A
Net Income
N/A
Guidance
Tone
Partnerships
Key Quotes
"Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of others"
"We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent"
Q3 2023
10-Q • Filed 11/2/2023
Summary
Regeneron delivered solid quarterly performance with $3.36B in revenue and $1.01B in net income. The company continues to manage multiple strategic collaborations across pharmaceuticals while navigating complex legal and regulatory challenges.
Revenue
$3.36B
Net Income
$1.01B
Guidance
Tone
Capex
$467.2M
Partnerships
Key Quotes
"Continuing to expand collaboration partnerships across multiple therapeutic areas"
"Maintaining strong financial performance despite ongoing patent and regulatory proceedings"
Q2 2023
10-Q • Filed 8/3/2023
Summary
Regeneron delivered strong Q2 2023 financial results with revenues of $3.16 billion and net income of $968.4 million. The company maintains a robust pipeline and continues to invest in R&D while facing some patent and regulatory challenges.
Revenue
$3.16B
Net Income
$968.4M
Guidance
Tone
Capex
$291.2M
Partnerships
Key Quotes
"Our core business strategy is to maintain a strong foundation in basic scientific research and discovery-enabling technologies"
"Our objective is to continue to advance as an integrated, multi-product biotechnology company"
Q1 2023
10-Q • Filed 5/4/2023
Summary
Regeneron delivered strong Q1 2023 financial results with robust revenue of $3.16 billion and net income of $817.8 million. Key products like Dupixent and Libtayo continue to show growth, while the company maintains a diversified portfolio and strategic collaborations.
Revenue
$3.16B
Net Income
$817.8M
Guidance
Tone
Capex
$178.2M
Partnerships
Key Quotes
"Our core business strategy is to maintain a strong foundation in basic scientific research and discovery-enabling technologies"
"Our objective is to continue to advance as an integrated, multi-product biotechnology company"
Sector Comparison
How REGN performs vs Healthcare sector and Biotech peers